Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

David S. Boss(The Netherlands Cancer Institute), Petronella O. Witteveen(University Medical Center Utrecht), J. van der Sar(The Netherlands Cancer Institute), Martijn P. Lolkema(University Medical Center Utrecht), Emile E. Voest(University Medical Center Utrecht), Paul K. Stockman(AstraZeneca (United Kingdom)), Ö. Ataman(AstraZeneca (United Kingdom)), David M. Wilson(AstraZeneca (United Kingdom)), Shampa Das(AstraZeneca (United Kingdom)), Jan H.M. Schellens(The Netherlands Cancer Institute)
Annals of Oncology
October 18, 2010
10.1093/annonc/mdq344
Cited by 109Open Access
Full Text

Abstract

Related Papers

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k
The cellular geography of Aurora kinases
Mar Carmena, William C. Earnshaw|Nature Reviews Molecular Cell Biology|2003|1.1k
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Richard Simon, Larry Rubinstein, Susan G. Arbuck et al.|JNCI Journal of the National Cancer Institute|1997|640
Aurora Kinases as Anticancer Drug Targets
Oliver Gautschi, Jim Heighway, Philip C. Mack et al.|Clinical Cancer Research|2008|384
AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis
Robert W. Wilkinson, Rajesh Odedra, Simon P. Heaton et al.|Clinical Cancer Research|2007|357